Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0E3HC
|
||||
Former ID |
DNC004162
|
||||
Drug Name |
L000021649
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C23H24N4OS
|
||||
Canonical SMILES |
C1CCN(CC1)CCOC2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CSC=C5)N=C<br />3
|
||||
InChI |
1S/C23H24N4OS/c1-2-9-26(10-3-1)11-12-28-21-6-4-18(5-7-21)20-14-24-23-22(15-25-27(23)16-20)19-8-13-29-17-19/h4-8,13-17H,1-3,9-12H2
|
||||
InChIKey |
VOYMOBPSYVKQGF-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Vascular endothelial growth factor receptor 2 | Target Info | Inhibitor | [1] | |
KEGG Pathway | Ras signaling pathway | ||||
Rap1 signaling pathway | |||||
Cytokine-cytokine receptor interaction | |||||
Endocytosis | |||||
PI3K-Akt signaling pathway | |||||
VEGF signaling pathway | |||||
Focal adhesion | |||||
Proteoglycans in cancer | |||||
NetPath Pathway | IL2 Signaling Pathway | ||||
PANTHER Pathway | Angiogenesis | ||||
VEGF signaling pathway | |||||
Pathway Interaction Database | HIF-2-alpha transcription factor network | ||||
Beta3 integrin cell surface interactions | |||||
Signaling events mediated by TCPTP | |||||
SHP2 signaling | |||||
S1P1 pathway | |||||
VEGF and VEGFR signaling network | |||||
Integrins in angiogenesis | |||||
Signaling events mediated by VEGFR1 and VEGFR2 | |||||
Notch-mediated HES/HEY network | |||||
Reactome | Neurophilin interactions with VEGF and VEGFR | ||||
VEGF binds to VEGFR leading to receptor dimerization | |||||
Integrin cell surface interactions | |||||
EPHA-mediated growth cone collapse | |||||
VEGFA-VEGFR2 Pathway | |||||
VEGFR2 mediated cell proliferation | |||||
WikiPathways | Focal Adhesion | ||||
Nifedipine Activity | |||||
Cardiac Progenitor Differentiation | |||||
Signaling by VEGF | |||||
Angiogenesis | |||||
References | |||||
REF 1 | Bioorg Med Chem Lett. 2002 Dec 16;12(24):3537-41.Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.